107 related articles for article (PubMed ID: 16317287)
1. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.
Nicholson B; Lloyd GK; Miller BR; Palladino MA; Kiso Y; Hayashi Y; Neuteboom ST
Anticancer Drugs; 2006 Jan; 17(1):25-31. PubMed ID: 16317287
[TBL] [Abstract][Full Text] [Related]
2. Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models.
Reipsch F; Biersack B; Lucas H; Schobert R; Mueller T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884888
[TBL] [Abstract][Full Text] [Related]
3. Tubulin-interactive natural products as anticancer agents.
Kingston DG
J Nat Prod; 2009 Mar; 72(3):507-15. PubMed ID: 19125622
[TBL] [Abstract][Full Text] [Related]
4. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG
Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents.
Maguire CJ; Chen Z; Mocharla VP; Sriram M; Strecker TE; Hamel E; Zhou H; Lopez R; Wang Y; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
Medchemcomm; 2018 Oct; 9(10):1649-1662. PubMed ID: 30429970
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug design.
Wang T; Wu C; Wang C; Zhang G; Arnst KE; Yao Y; Zhang Z; Wang Y; Pu D; Li W
Biochem Biophys Res Commun; 2020 Feb; ():. PubMed ID: 32085900
[TBL] [Abstract][Full Text] [Related]
7. Keep an Eye on Your NPI.
Benzoni T
Fam Pract Manag; 2024 May; 31(3):39-40. PubMed ID: 38743793
[No Abstract] [Full Text] [Related]
8. A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells.
Singh AV; Bandi M; Raje N; Richardson P; Palladino MA; Chauhan D; Anderson KC
Blood; 2011 May; 117(21):5692-700. PubMed ID: 21454451
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.
Millward M; Mainwaring P; Mita A; Federico K; Lloyd GK; Reddinger N; Nawrocki S; Mita M; Spear MA
Invest New Drugs; 2012 Jun; 30(3):1065-73. PubMed ID: 21327495
[TBL] [Abstract][Full Text] [Related]
10. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
[TBL] [Abstract][Full Text] [Related]
11. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
Meng F; Cai X; Duan J; Matteucci MG; Hart CP
Cancer Chemother Pharmacol; 2008 May; 61(6):953-63. PubMed ID: 17639393
[TBL] [Abstract][Full Text] [Related]
12. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.
Bertelsen LB; Shen YY; Nielsen T; Stødkilde-Jørgensen H; Lloyd GK; Siemann DW; Horsman MR
Int J Radiat Biol; 2011 Nov; 87(11):1126-34. PubMed ID: 21815749
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.
Mita MM; Spear MA; Yee LK; Mita AC; Heath EI; Papadopoulos KP; Federico KC; Reich SD; Romero O; Malburg L; Pilat M; Lloyd GK; Neuteboom ST; Cropp G; Ashton E; LoRusso PM
Clin Cancer Res; 2010 Dec; 16(23):5892-9. PubMed ID: 21138873
[TBL] [Abstract][Full Text] [Related]
14. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.
Martin K; Müller P; Schreiner J; Prince SS; Lardinois D; Heinzelmann-Schwarz VA; Thommen DS; Zippelius A
Cancer Immunol Immunother; 2014 Sep; 63(9):925-38. PubMed ID: 24906866
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
[TBL] [Abstract][Full Text] [Related]
16. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
Ji YT; Liu YN; Liu ZP
Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
[TBL] [Abstract][Full Text] [Related]
17. Drug discovery targeting cell division proteins, microtubules and FtsZ.
Ojima I; Kumar K; Awasthi D; Vineberg JG
Bioorg Med Chem; 2014 Sep; 22(18):5060-77. PubMed ID: 24680057
[TBL] [Abstract][Full Text] [Related]
18. Medicinal chemistry and chemical biology of diketopiperazine-type antimicrotubule and vascular-disrupting agents.
Hayashi Y; Yamazaki-Nakamura Y; Yakushiji F
Chem Pharm Bull (Tokyo); 2013; 61(9):889-901. PubMed ID: 23995353
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
Ricart AD; Ashton EA; Cooney MM; Sarantopoulos J; Brell JM; Feldman MA; Ruby KE; Matsuda K; Munsey MS; Medina G; Zambito A; Tolcher AW; Remick SC
Cancer Chemother Pharmacol; 2011 Oct; 68(4):959-70. PubMed ID: 21305290
[TBL] [Abstract][Full Text] [Related]
20. CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo.
Burns CJ; Fantino E; Phillips ID; Su S; Harte MF; Bukczynska PE; Frazzetto M; Joffe M; Kruszelnicki I; Wang B; Wang Y; Wilson N; Dilley RJ; Wan SS; Charman SA; Shackleford DM; Fida R; Malcontenti-Wilson C; Wilks AF
Mol Cancer Ther; 2009 Nov; 8(11):3036-45. PubMed ID: 19887548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
